TCM Ltd
Incorporated in 1943, TCM Ltd manufactures chemicals having and trades solar equipments and healthcare devices[1]
- Market Cap ₹ 47.9 Cr.
- Current Price ₹ 64.1
- High / Low ₹ 81.0 / 35.0
- Stock P/E 24.1
- Book Value ₹ 48.2
- Dividend Yield 0.00 %
- ROCE 9.30 %
- ROE 9.20 %
- Face Value ₹ 10.0
Pros
- Debtor days have improved from 145 to 99.5 days.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 0.75% over last 3 years.
- Company might be capitalizing the interest cost
- Earnings include an other income of Rs.5.33 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Commodity Chemicals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 0.40 | 0.92 | 4.23 | 3.46 | 7.16 | 31.65 | 24.73 | 21.24 | |
| 1.22 | 0.43 | 0.50 | 0.72 | 0.35 | 1.26 | 1.67 | 4.27 | 5.78 | 9.71 | 32.01 | 25.45 | 22.95 | |
| Operating Profit | -1.22 | -0.43 | -0.50 | -0.72 | -0.35 | -0.86 | -0.75 | -0.04 | -2.32 | -2.55 | -0.36 | -0.72 | -1.71 |
| OPM % | -215.00% | -81.52% | -0.95% | -67.05% | -35.61% | -1.14% | -2.91% | -8.05% | |||||
| 0.05 | 0.02 | 0.06 | 0.22 | -0.39 | 0.04 | 1.15 | 1.23 | -1.56 | 0.23 | 0.82 | 4.60 | 5.33 | |
| Interest | -0.00 | -0.00 | -0.00 | 0.05 | 0.01 | 0.12 | 0.01 | 0.01 | 0.01 | 0.27 | 0.15 | 0.60 | 1.47 |
| Depreciation | 0.28 | 0.07 | 0.06 | 0.06 | -0.00 | -0.00 | 0.01 | 0.02 | 0.04 | 0.19 | 0.07 | 0.16 | 0.24 |
| Profit before tax | -1.45 | -0.48 | -0.50 | -0.61 | -0.75 | -0.94 | 0.38 | 1.16 | -3.93 | -2.78 | 0.24 | 3.12 | 1.91 |
| Tax % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | 15.52% | -0.00% | -0.72% | 16.67% | -0.96% | |
| -1.44 | -0.48 | -0.50 | -0.61 | -0.75 | -0.95 | 0.39 | 0.98 | -3.93 | -2.77 | 0.20 | 3.15 | 1.99 | |
| EPS in Rs | -1.92 | -0.64 | -0.67 | -0.81 | -1.00 | -1.27 | 0.52 | 1.31 | -5.24 | -3.70 | 0.27 | 4.21 | 2.66 |
| Dividend Payout % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 93% |
| 3 Years: | 93% |
| TTM: | -32% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 24% |
| 5 Years: | 54% |
| 3 Years: | 58% |
| TTM: | 206% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 18% |
| 3 Years: | 11% |
| 1 Year: | 30% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 0% |
| 3 Years: | 1% |
| Last Year: | 9% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.40 | 3.40 | 3.40 | 3.40 | 3.40 | 3.40 | 3.40 | 3.40 | 3.40 | 7.48 | 7.48 | 7.48 | 7.48 |
| Reserves | -27.69 | -29.20 | -29.70 | -30.31 | 30.33 | 29.02 | 29.16 | 30.14 | 23.73 | 26.90 | 27.10 | 30.36 | 28.57 |
| 24.28 | 24.69 | 25.15 | 6.30 | 5.38 | 5.38 | 5.64 | 5.83 | 6.02 | 1.08 | 0.27 | 11.22 | 20.63 | |
| 7.26 | 7.28 | 7.29 | 26.73 | 25.74 | 31.35 | 27.23 | 29.14 | 30.19 | 37.04 | 54.92 | 34.08 | 33.69 | |
| Total Liabilities | 7.25 | 6.17 | 6.14 | 6.12 | 64.85 | 69.15 | 65.43 | 68.51 | 63.34 | 72.50 | 89.77 | 83.14 | 90.37 |
| 2.49 | 1.39 | 1.33 | 1.26 | 58.01 | 58.01 | 58.01 | 58.42 | 54.70 | 35.12 | 16.85 | 13.59 | 13.51 | |
| CWIP | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 2.05 |
| Investments | 0.24 | 0.24 | 0.24 | 0.24 | 0.80 | 0.44 | 0.19 | 0.19 | 0.17 | 0.52 | 0.91 | 1.62 | 1.83 |
| 4.52 | 4.54 | 4.57 | 4.62 | 6.04 | 10.70 | 7.23 | 9.90 | 8.47 | 36.86 | 72.01 | 67.93 | 72.98 | |
| Total Assets | 7.25 | 6.17 | 6.14 | 6.12 | 64.85 | 69.15 | 65.43 | 68.51 | 63.34 | 72.50 | 89.77 | 83.14 | 90.37 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.31 | -0.40 | -0.43 | -0.72 | -4.39 | -1.63 | -0.56 | -0.11 | -2.79 | -9.56 | 3.74 | -10.79 | |
| -0.00 | -0.00 | -0.00 | -0.00 | 3.98 | -0.01 | -0.01 | -0.04 | 2.81 | 4.39 | -2.78 | 0.53 | |
| 0.32 | 0.41 | 0.47 | 0.83 | 0.15 | 5.32 | -3.14 | 0.18 | 0.20 | 4.99 | -0.94 | 10.37 | |
| Net Cash Flow | 0.01 | 0.01 | 0.03 | 0.10 | -0.25 | 3.68 | -3.70 | 0.03 | 0.22 | -0.18 | 0.01 | 0.11 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 1,377.88 | 706.20 | 217.45 | 195.16 | 238.07 | 97.45 | 99.48 | |||||
| Inventory Days | 1,477.38 | 847.92 | 467.90 | 192.33 | 269.13 | 480.07 | 570.68 | |||||
| Days Payable | 2,581.07 | 1,914.85 | 747.47 | 65.98 | 71.72 | 42.86 | 47.36 | |||||
| Cash Conversion Cycle | 274.18 | -360.73 | -62.13 | 321.51 | 435.48 | 534.66 | 622.80 | |||||
| Working Capital Days | -10,986.50 | -3,209.62 | -812.84 | -1,301.76 | -474.60 | 97.45 | -53.72 | |||||
| ROCE % | -268.52% | -1.30% | -2.13% | 1.03% | 2.04% | -4.72% | -7.32% | 1.11% | 9.30% |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication 13 Nov
-
Board Meeting Outcome for And The Consolidated And Standalone Unaudited Financial Results Along With The Consolidated And Standalone Limited Review Reports For The Quarter Ended 30Th September 2025
11 Nov - Unaudited Q2 results for quarter ended 30 Sep 2025; proposed Better Feeds acquisition ₹765 lakh; ₹102.56 lakh advance paid.
-
Intimation Under Regulation 30 Of The SEBI(LODR) Regulations 2015 For Opening Of The Healthcare Division Office Of The Company
10 Nov - Opened Healthcare Division office in Maradu, Ernakulam; 1,621 sq ft; 10 Nov 2025.
-
Board Meeting Intimation for Consideration And Approval Of The Consolidated And Standalone Unaudited Financial Results For The Quarter Ended 30Th September 2025
29 Oct - Board meeting 11 Nov 2025 to approve Q2 (30 Sep 2025) unaudited financial results; trading window remains closed.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
14 Oct - Confirmation Certificate under Regulation 74(5) of SEBI(Depositories and Participants) Regulations, 2018 for the quarter ending 30th September 2025 received from our RTA, M/s Cameo Corporate …
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Overview:[1]
Company trading of medical products,
GPS-enabled Automatic Headlight Beam Assist System for vehicles under the brand name of ENSO, and the business of setting up and commissioning Solar Power plants